Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.56 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.56 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.56 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7331861 | 0.92 | PLAAT3 (0.57) | CA12CA1CA2CA9POLB | |
| SCHEMBL11602508 | 0.90 | PKM (0.62) | CA12CA1CA2CA9POLB | |
| SCHEMBL3209768 | 0.89 | GAA (0.60) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL3204252 | 0.89 | ALOX5 (0.63) | ALDH1A1ADRB2 | |
| SCHEMBL3187109 | 0.87 | KDM4E (0.64) | CA12CA1CA2CA9POLB | |
| SCHEMBL7435099 | 0.86 | ATM (0.76) | CA12CA1CA2CA9POLB | |
| SCHEMBL347209 | 0.84 | FFAR4 (0.61) | CA12CA1CA2CA9ATM | |
| Hydrochloric Acid SCHEMBL11808765 | 0.84 | ATM (0.73) | CA12CA1CA2CA9POLB | |
| SCHEMBL3199504 | 0.84 | KMT2A (0.54) | CA12CA1CA2CA9POLB | |
| SCHEMBL16980880 | 0.83 | GAA (0.55) | POLBALDH1A1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | CA12 4689/4885CA1 4651/4885CA2 2941/4885 |
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | F13B, FGB, TGFB1 | CA12 2028/4885CA1 1175/4885CA2 1729/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | CA12 4676/4885CA1 4609/4885CA2 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.